Stocklytics Platform
Asset logo for symbol NTLA
Intellia Therapeutics
NTLA57
$25.08arrow_drop_down3.87%-$1.01
Asset logo for symbol NTLA
NTLA57

$25.08

arrow_drop_down3.87%
Key Stats
Open$26.13
Prev. Close$26.09
EPS-5.37
DividendNon-Dividend
Next Earnings Date-
Dividend Yield %-
PE Ratio-
LOWHIGH
Day Range24.97
26.28
52 Week Range19.37
46.00
Ratios
EPS-5.37
Fundamentals
Payout Ratio-
Industry average yield2.86%
Last Dividend pay date-
Dividend per share-
Dividend yield forecast-

Stock Analysis

Technicals

Summarizing what the indicators are suggesting.

Strong Buy
Buy
Neutral
Sell
Strong Sell
Analyst rating

An aggregate view of professional's ratings.

Strong Buy
Buy
Neutral
Sell
Strong Sell

Stock Performance

NTLAarrow_drop_up0.04%
US Healthcare Sectorarrow_drop_down0.14%
US Marketarrow_drop_up0.88%
warning
NTLA / Market
NTLA lose to the US Market which returned 0.88% over the last twenty four hours.
check_circle
NTLA / Healthcare Sector
NTLA exceeded the US Healthcare sector which returned -0.14% over the last twenty four hours.

Intellia Therapeutics (NTLA) Statistics

Intellia Therapeutics Inc (NTLA) is a biotechnology company that focuses on developing and commercializing gene editing technologies. The company's main platform is CRISPR/Cas9, a revolutionary gene editing tool that allows scientists to modify genes with unprecedented precision. With this technology, Intellia aims to develop novel therapies for a wide range of diseases, including genetic disorders, cancer, and infectious diseases. As of the latest statistics, NTLA has a market capitalization of $4.5 billion and a current share price of $130. The stock has a 52-week high of $155 and a 52-week low of $56.

When it comes to valuation metrics, NTLA has a forward price-to-earnings (P/E) ratio of 80. This indicates that investors expect strong future earnings growth from the company. NTLA also has a price-to-sales (P/S) ratio of 73, suggesting that the stock is trading at a premium compared to its revenue. In terms of fundamentals, NTLA has a positive earnings per share (EPS) of $1.50 and a return on equity (ROE) of 13%. These numbers reflect the company's ability to generate profits and provide a return to its shareholders.

add Intellia Therapeutics  to watchlist

Keep an eye on Intellia Therapeutics

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

search
help
How has Intellia Therapeutics (NTLA) stock's performance compared to its sector and the market over the past year?

Over the past year, Intellia Therapeutics (NTLA) has experienced a price change of . Compared to the Healthcare sector, which saw a change of 25.13%, Intellia Therapeutics has underperformed compared to its sector, indicating its relative standing within the Healthcare sector. Against the broader market's change of 50.53%, it has fallen short of the market average. This comparison highlights Intellia Therapeutics 's performance relative to both its sector and the overall market over the last year.

help
What is the PE ratio of Intellia Therapeutics (NTLA) stock?

The PE ratio for Intellia Therapeutics (NTLA) is currently not available. This could be due to a variety of factors such as the company not having positive earnings at the moment or recent updates not being reflected.

help
What is the EPS of Intellia Therapeutics (NTLA) stock?

The Earnings Per Share (EPS) for Intellia Therapeutics (NTLA), calculated on a diluted basis, is -$5.37. EPS is a key indicator of a company's profitability, showing the portion of a company's profit allocated to each outstanding share of common stock.

help
What is the operating margin of Intellia Therapeutics (NTLA) stock?

The operating margin for Intellia Therapeutics (NTLA) is -394%. This metric represents the percentage of revenue that remains after paying for variable production costs, indicating the efficiency and profitability of the company's core business operations.

help
What is the EBITDA of Intellia Therapeutics (NTLA) stock?

The EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) of Intellia Therapeutics (NTLA) is -$507.9M. EBITDA is a widely used earnings metric to assess a company's operational efficiency and profitability before the impact of non-operating decisions such as financing, accounting, and tax environments.

help
How much debt does Intellia Therapeutics (NTLA) have?

Intellia Therapeutics (NTLA) has a total debt of $110.86M. The net debt, which accounts for cash and cash equivalents against the total debt, is -$61.12M.

email

Sign up for our newsletter

Join our exclusive community of over one million investment enthusiasts and receive our free newsletter filled with analysis, news, and updates every weekday.

Take Your Investments to a Whole New Level